GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » argenx SE (OTCPK:ARGNF) » Definitions » Short Percentage of Float

ARGNF (argenx SE) Short Percentage of Float


View and export this data going back to 2015. Start your Free Trial

What is argenx SE Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of argenx SE's Short Percentage of Float

For the Biotechnology subindustry, argenx SE's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

argenx SE's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, argenx SE's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where argenx SE's Short Percentage of Float falls into.


;
;

argenx SE Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » argenx SE (OTCPK:ARGNF) » Definitions » Short Percentage of Float
Comparable Companies
XBRU:UCB XBRU:TUB XBRU:ONWD XBRU:HYL XBRU:ALEMS XBRU:BIOS XBRU:OXUR VRTX ASX:CSL REGN XKRX:207940 ALNY ONC BNTX XKRX:068270 SMMT UTHR INSM XKRX:196170 RPRX
Traded in Other Exchanges
ARGX:USA ARGXb:UK 0QW0:UK 1AEA:Germany 1AE:Germany 1AE:Germany A1RG34:Brazil ARGX:Belgium ARGX:Austria
Address
Laarderhoogtweg 25, Amsterdam, NH, NLD, 1101EB
Website
https://www.argenx.com
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.